TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3918196

Group type: EXPERIMENTAL
Intervention: 15% glucose‐3.3% Intralipid‐5% amino acid solution (group G‐F)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 25% glucose‐5% amino acid solution (group G)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both regimens (group G and group G‐F)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intralipid addition to TPN regimen
Number of subjects: 40
Study: 31706658

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen (HFNC) at a flow of 60 L/min
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional reserve-bag oxygen therapy (NBO2) at a flow of 15 L/min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen (HFNC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional reserve-bag oxygen therapy (NBO2)
Number of subjects: 22
Study: 31286899

Group type: EXPERIMENTAL
Intervention: Pharyngeal packing (PP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No pharyngeal packing (non-PP)
Number of subjects: 88
Study: 29231609

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 50
Study: 25261953

Group type: EXPERIMENTAL
Intervention: Breathing imagery task
Number of subjects: 6

Group type: COMPARATOR
Intervention: Braille music code task
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nonimagery activity (cloze passage)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (nonimagery tasks)
Number of subjects: 6
Study: 23283500

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score (MDS)
Number of subjects: 3083

Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Dietary Pattern Score (MSDPS)
Number of subjects: 3083
Study: 21992464

Group type: EXPERIMENTAL
Intervention: HGF/c-Met signaling activation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: HGF activation in liver cancer cell lines (HuH-6 and HuH-7)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nuclear expression of c-Met-activated beta-catenin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: CTNNB1 mutation analysis
Number of subjects: 98
Study: 18328929

Group type: EXPERIMENTAL
Intervention: 100 mug CYT006-AngQb
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 300 mug CYT006-AngQb
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 17283866

Group type: EXPERIMENTAL
Intervention: Nifedipine CR
Number of subjects: 505

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 505
Study: 14678103

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation during cardiac surgery
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no RF ablation)
Number of subjects: 130
Study: 10972687

Group type: EXPERIMENTAL
Intervention: Prednisolone 60 mg/m2 daily for six weeks, followed by 40 mg/m2 on alternate days for six weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prednisolone 40 mg/m2 daily for six weeks
Number of subjects: 68
Study: 8774278

Group type: EXPERIMENTAL
Intervention: Transvaginal color Doppler sonography
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (spontaneous ovulatory cycles)
Number of subjects: 90
Study: 1473873

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride in polyethylene glycol (MHP) suppository
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Morphine alkaloid in Novata BBC (MAN) suppository
Number of subjects: 17
Study: 6202753

Group type: EXPERIMENTAL
Intervention: Ketoconazole, 400 mg once daily (K)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amphotericin B tablets and lozenges (A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both ketoconazole and amphotericin B together (K + A)
Number of subjects: 48
Study: 31623622

Group type: EXPERIMENTAL
Intervention: 3D Oculus Rift CV1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laptop (LCD)
Number of subjects: 20
Study: 29687877

Group type: EXPERIMENTAL
Intervention: Exogenous adiponectin in addition to adenosine and tirofiban
Number of subjects: 66

Group type: COMPARATOR
Intervention: Adenosine combined with micro-pump intravenous infusion of tirofiban
Number of subjects: 66
Study: 27017450

Group type: EXPERIMENTAL
Intervention: Internet-delivered ISTDP (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (n = 50)
Number of subjects: 100
Study: 25052420

Group type: EXPERIMENTAL
Intervention: Early intervention (SHGs and microfinance at baseline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late intervention (SHGs and microfinance after 18 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late intervention
Number of subjects: 0
Study: 22008899

Group type: EXPERIMENTAL
Intervention: Combination therapy (topiramate plus nortriptyline)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Monotherapy (placebo)
Number of subjects: 68
Study: 19353332

Group type: EXPERIMENTAL
Intervention: Skin adhesive (n = 53)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcuticular suture (n = 47)
Number of subjects: 100
Study: 17337492

Group type: EXPERIMENTAL
Intervention: Telmisartan 40/80 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ramipril 5/10 mg
Number of subjects: 96
Study: 15114377

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1.250 mg twice daily (500 mg Ca2+ per tablet)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1.250 mg twice daily plus 400 IU vitamin D3 b.i.d.
Number of subjects: 16
Study: 11770035

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting with CPB
Number of subjects: 26
Study: 9421346

Group type: EXPERIMENTAL
Intervention: Psychoeducational medication management training (PMT) + cognitive psychotherapy (CP) + key‐person counselling (KC)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Various combinations of PMT, CP, and KC
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (non-specifically treated patients)
Number of subjects: 132
Study: 8318411

Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy in biochemically defined responders
Number of subjects: 67

Group type: COMPARATOR
Intervention: Maintenance hormones after 6 months
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Continue chemotherapy while biochemical markers kept falling or remained normal
Number of subjects: 67
Study: 3011917

Group type: EXPERIMENTAL
Intervention: Intranasal recombinant alpha interferon (IFN‐alpha 2b) 1,500,000 IU twice daily
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intranasal recombinant alpha interferon (IFN‐alpha 2b)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intranasal recombinant alpha interferon (IFN‐alpha 2b) or placebo once daily
Number of subjects: 400
Study: 30776365

Group type: EXPERIMENTAL
Intervention: Antibiotic management based on rapid diagnostic testing (RDT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Antibiotic management based on RDT
Number of subjects: 45
Study: 28728785

Group type: EXPERIMENTAL
Intervention: Clampless facilitating device (CFD) during off-pump CABG
Number of subjects: 142

Group type: COMPARATOR
Intervention: Partial clamp during off-pump CABG
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Single-clamp during on-pump CABG
Number of subjects: 142

Group type: COMPARATOR
Intervention: Double-clamp during on-pump CABG
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 1 CFD during off-pump CABG
Number of subjects: 142

Group type: COMPARATOR
Intervention: >1 CFD during off-pump CABG
Number of subjects: 142
Study: 26715485

Group type: EXPERIMENTAL
Intervention: 40 IU of intranasal OXT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 25726222

Group type: EXPERIMENTAL
Intervention: Rehydration group (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dehydration group (n=7)
Number of subjects: 14
Study: 22027875

Group type: EXPERIMENTAL
Intervention: Generic LPV/r 200/50mg BID
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Branded LPV/r 200/50mg BID
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both generic and branded LPV/r
Number of subjects: 20
Study: 19616493

Group type: EXPERIMENTAL
Intervention: LAIV+OPV
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Placebo+OPV
Number of subjects: 2503

Group type: EXPERIMENTAL
Intervention: LAIV only
Number of subjects: 2503
Study: 17884346

Group type: EXPERIMENTAL
Intervention: Botanical formulation (rose hips, blueberry and blackberry mixture, grapevine extract)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Botanical formulation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 15181844

Group type: EXPERIMENTAL
Intervention: Respiratory rate set to 12 times per minute for 30 minutes, adjusted according to calculation with 0.3 x PaCO2
Number of subjects: 42

Group type: COMPARATOR
Intervention: Respiratory rate set to 8 times per minute
Number of subjects: 42
Study: 12126522

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.0 g/d (body weight < 50 kg) or 1.5 g/d (body weight > 50 kg), reduced to 0.75-1.0 g/d after 6 months, maintaining dosage of 0.5-0.75 g/d after 12 months, total treatment duration at least 12 months.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group received prednisone orally at 0.8 mg/kg/d.
Number of subjects: 62
Study: 10530284

Group type: EXPERIMENTAL
Intervention: Active vertical corrector (AVC) treatment followed by fixed 022 orthodontic appliances
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 29
Study: 7548920

Group type: EXPERIMENTAL
Intervention: 5 g lactulose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 g inulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 g lactulose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 g inulin
Number of subjects: 8

Group type: COMPARATOR
Intervention: resistant starch (6.1 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: inulin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: lactulose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: starch
Number of subjects: 8
Study: 2039059

Group type: COMPARATOR
Intervention: Taping
Number of subjects: 30

Group type: COMPARATOR
Intervention: Swede‐O brace
Number of subjects: 30

Group type: COMPARATOR
Intervention: Kallassy brace
Number of subjects: 30
Study: 6783524

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition regimen consisting of 0.6 g amino acid and 4.0 g carbohydrate/kg BW/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Isocaloric amounts of carbohydrate (5.0 g/kg BW/day) alone
Number of subjects: 55
Study: 31161236

Group type: EXPERIMENTAL
Intervention: 14 baths in thermal water for a month plus standard pharmacological treatment (Group A Phase 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard pharmacological treatment (Group B Phase 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment (Group A Phase 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 14 baths in thermal water for a month plus standard treatment (Group B Phase 2)
Number of subjects: 50
Study: 28085977

Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer (TD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA; distilled water)
Number of subjects: 20
Study: 26336909

Group type: EXPERIMENTAL
Intervention: 6-week intranasal administration of oxytocin
Number of subjects: 20
Study: 22933619

Group type: EXPERIMENTAL
Intervention: School-based validating interview for adolescents who self-injure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 66
Study: 21876564

Group type: EXPERIMENTAL
Intervention: 15 mg A3309
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg A3309
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18504093

Group type: EXPERIMENTAL
Intervention: Palliative care psychoeducational intervention
Number of subjects: 256
Study: 17723083

Group type: EXPERIMENTAL
Intervention: Combination therapy with amiodarone and sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sotalol monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone monotherapy
Number of subjects: 0
Study: 14985946

Group type: EXPERIMENTAL
Intervention: Bone mass consolidation during growth
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Volumetric BMD (vBMD) at the lumbar spine and ultradistal radius (UDR) in women
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Volumetric BMD (vBMD) at the femoral neck (FN) and UDR in men
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Peak vBMD at the lumbar spine
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Peak vBMD at the femoral neck
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Peak vBMD at the UDR
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Bone size during consolidation
Number of subjects: 266
Study: 10763787

Group type: EXPERIMENTAL
Intervention: Fluids prepared using a viscometer
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluids prepared subjectively by nursing staff
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 8833170

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Injective immunotherapy (SIT)
Number of subjects: 23
Study: 1579515

Group type: EXPERIMENTAL
Intervention: Food additives (tartrazine and benzoates) confirmed with diet and double blind challenge
Number of subjects: 2
Study: 6391562

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Meditation (noncultic)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 52
Study: 3830240

Group type: EXPERIMENTAL
Intervention: FCE20700 (1 mg, 2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: FCE20700 (2 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31962003

Group type: EXPERIMENTAL
Intervention: Educational intervention (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 75
Study: 29722834

Group type: EXPERIMENTAL
Intervention: Caloric sweeteners (50 g glucose and 25 g fructose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Noncaloric sweetener (220 mg acesulfame-K)
Number of subjects: 12
Study: 26494130

Group type: EXPERIMENTAL
Intervention: Panobinostat in combination with bortezomib and dexamethasone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panobinostat (MTD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panobinostat exposure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panobinostat with dexamethasone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panobinostat without dexamethasone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panobinostat single-agent trials
Number of subjects: 12
Study: 24633858

Group type: EXPERIMENTAL
Intervention: Dementia Education Programme Incorporating Reminiscence for Staff
Number of subjects: 0
Study: 22168539

Group type: EXPERIMENTAL
Intervention: Ostim
Number of subjects: 14

Group type: COMPARATOR
Intervention: Natural healing (Control)
Number of subjects: 14
Study: 20096638

Group type: EXPERIMENTAL
Intervention: Depotestosterone + Anastrozole (T-A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Depotestosterone + Placebo (T-P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 19142476

Group type: EXPERIMENTAL
Intervention: Information with previous delivery of emergency contraception (Medicated Group)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Information only (Control Group)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Medicated Group
Number of subjects: 823

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 823
Study: 16895639

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) pretreatment with recombinant human FSH (r-hFSH) starting on day 2 or 3 after OC withdrawal.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group receiving r-hFSH starting on day 2 of a natural cycle.
Number of subjects: 64
Study: 14517771

Group type: EXPERIMENTAL
Intervention: Competitive cyclists
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ex-cyclists
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active sportsmen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Competitive cycling
Number of subjects: 42
Study: 11030186

Group type: EXPERIMENTAL
Intervention: Creon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancrease
Number of subjects: 60
Study: 8752186

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 1373779

Group type: COMPARATOR
Intervention: Finasteride (5 to 80 mg per day) for 12 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Finasteride (0.2 to 40 mg per day) for 24 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Finasteride (1 and 5 mg groups combined)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Finasteride (1 and 5 mg groups)
Number of subjects: 190
Study: 4040050

Group type: EXPERIMENTAL
Intervention: Reglan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Reglan and Solu‐medrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30676135

Group type: EXPERIMENTAL
Intervention: CHO + PRO (protein from beef and whey mixed with orange juice)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CHO (nonprotein isoenergetic carbohydrate)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 25

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 25
Study: 29796851

Group type: EXPERIMENTAL
Intervention: Esoxx® (hyaluronic acid and chondroitin sulfate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 27820821

Group type: EXPERIMENTAL
Intervention: Dengue interventions (DEN)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Combined diarrhea and dengue interventions (DIADEN)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Diarrhea interventions (DIA)
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 1301
Study: 25317619

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate solution (3 ml/kg of sodium bicarbonate solution (150 mEq/L) one hour prior to procedure and then drip rate decreased to 1 ml/kg/hour until 6 hours post procedure)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sodium chloride solution (1 ml/kg/hour of normal saline solution, starting 12 hours before and continuing 12 hours after iohexol contrast)
Number of subjects: 220
Study: 22360500

Group type: EXPERIMENTAL
Intervention: Palindrome catheter (PC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Step-tip catheter (SC)
Number of subjects: 97
Study: 19602993

Group type: EXPERIMENTAL
Intervention: Light protected parenteral nutrition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Light exposed parenteral nutrition
Number of subjects: 40
Study: 19083385

Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation (4.5 g x d(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (4.5 g x d(‐1) of maltodextrin)
Number of subjects: 0
Study: 16463921

Group type: EXPERIMENTAL
Intervention: Conditional cash transfers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing family and community migration networks
Number of subjects: 0
Study: 12514675

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (20 minutes of ergometry training per day and 1 group training session per week for 5 months after 4 weeks of in-hospital training).
Number of subjects: 19

Group type: COMPARATOR
Intervention: In-hospital exercise training (60 minutes of bicycle ergometry per day for 4 weeks).
Number of subjects: 19
Study: 11078903

Group type: EXPERIMENTAL
Intervention: Older females (9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Young females (8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (young and older)
Number of subjects: 17
Study: 8720611

Group type: EXPERIMENTAL
Intervention: Initial 2-h post-load plasma glucose levels
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Fasting proinsulin levels
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Anthropometric characteristics, 2-h post-load specific insulin levels, fasting proinsulin/fasting insulin ratio
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of NIDDM
Number of subjects: 158
Study: 1359258

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5‐20 mg per day)
Number of subjects: 6797
Study: 3994881

Group type: EXPERIMENTAL
Intervention: Trichloroethylene (0.2 or 0.3 vol.%)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Halothane (0.2, 0.3, 0.4 or 0.5 vol.%)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Lower concentrations of volatile agents
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Trichloroethylene 0.3 vol.% or halothane 0.4 or 0.5 vol.%
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Trichloroethylene and halothane at recommended concentrations
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Trichloroethylene and halothane in cases of fetal compromise
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Breech presentation and prolongation of the U‐D interval
Number of subjects: 777
Study: 30957065

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 23
Study: 29917038

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Fruit and vegetables diet
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 329